NRx Pharmaceuticals Acquires Kadima Neuropsychiatry Institute

NRX Pharmaceuticals ( (NRXP) ) has shared an update.

On May 13, 2025, NRx Pharmaceuticals announced a definitive agreement to acquire Kadima Neuropsychiatry Institute, a leading site for CNS and psychedelic research. This acquisition is expected to enhance HOPE Therapeutics’ clinic network and is anticipated to be accretive to revenue and EBITDA for both NRx and HOPE. Dr. David Feifel, a renowned expert in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer. The acquisition aims to redefine mental healthcare access and delivery through innovative treatments and community-based care.

The most recent analyst rating on (NRXP) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.

Spark’s Take on NRXP Stock

According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.

NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.

To see Spark’s full report on NRXP stock, click here.

More about NRX Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. The company is advancing NRX-101, a Breakthrough Therapy for treatment-resistant bipolar depression and chronic pain, and has filed a New Drug Application for NRX-100 for suicidal depression. HOPE Therapeutics, a subsidiary of NRx, is building a network of interventional psychiatry clinics offering treatments like ketamine and TMS.

Average Trading Volume: 169,467

Technical Sentiment Signal: Strong Sell

Current Market Cap: $35.83M

See more data about NRXP stock on TipRanks’ Stock Analysis page.